A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects

NCT05679258 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: HLX15
DRUG: US-sourced DARZALEX®
DRUG: CN-sourced DARZALEX®
DRUG: EU-sourced DARZALEX®

Sponsor

Shanghai Henlius Biotech